vs
Northfield Bancorp, Inc.（NFBK）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Northfield Bancorp, Inc.的季度营收约是REGENXBIO Inc.的1.4倍（$41.3M vs $30.3M），REGENXBIO Inc.净利率更高（-221.3% vs -1545.5%，领先1324.2%），REGENXBIO Inc.同比增速更快（43.0% vs 12.7%），Northfield Bancorp, Inc.自由现金流更多（$52.5M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 15.0%）
诺斯菲尔德银行控股公司是总部位于美国的区域性银行机构，主要服务美国东北部市场，面向个人消费者、中小企业及本地社区客户提供储蓄存款、住房贷款、商业信贷、财富管理等多元银行服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NFBK vs RGNX — 直观对比
营收规模更大
NFBK
是对方的1.4倍
$30.3M
营收增速更快
RGNX
高出30.3%
12.7%
净利率更高
RGNX
高出1324.2%
-1545.5%
自由现金流更多
NFBK
多$105.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
15.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.3M | $30.3M |
| 净利润 | $-27.4M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -1263.3% | -190.0% |
| 净利率 | -1545.5% | -221.3% |
| 营收同比 | 12.7% | 43.0% |
| 净利润同比 | -343.6% | -31.2% |
| 每股收益（稀释后） | $-0.68 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NFBKRGNX
| Q4 25 | $41.3M | $30.3M | ||
| Q3 25 | $39.2M | $29.7M | ||
| Q2 25 | $38.9M | $21.4M | ||
| Q1 25 | $34.8M | $89.0M | ||
| Q4 24 | $36.7M | $21.2M | ||
| Q3 24 | $31.8M | $24.2M | ||
| Q2 24 | $31.5M | $22.3M | ||
| Q1 24 | $31.3M | $15.6M |
净利润NFBKRGNX
| Q4 25 | $-27.4M | $-67.1M | ||
| Q3 25 | $10.8M | $-61.9M | ||
| Q2 25 | $9.6M | $-70.9M | ||
| Q1 25 | $7.9M | $6.1M | ||
| Q4 24 | $11.3M | $-51.2M | ||
| Q3 24 | $6.5M | $-59.6M | ||
| Q2 24 | $6.0M | $-53.0M | ||
| Q1 24 | $6.2M | $-63.3M |
毛利率NFBKRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率NFBKRGNX
| Q4 25 | -1263.3% | -190.0% | ||
| Q3 25 | 37.7% | -176.3% | ||
| Q2 25 | 35.6% | -296.3% | ||
| Q1 25 | 31.0% | 13.6% | ||
| Q4 24 | 38.0% | -242.1% | ||
| Q3 24 | 27.9% | -256.6% | ||
| Q2 24 | 29.1% | -251.3% | ||
| Q1 24 | 27.2% | -408.8% |
净利率NFBKRGNX
| Q4 25 | -1545.5% | -221.3% | ||
| Q3 25 | 27.4% | -208.3% | ||
| Q2 25 | 24.6% | -331.8% | ||
| Q1 25 | 22.6% | 6.8% | ||
| Q4 24 | 30.7% | -241.3% | ||
| Q3 24 | 20.5% | -246.3% | ||
| Q2 24 | 18.9% | -237.7% | ||
| Q1 24 | 19.9% | -405.4% |
每股收益（稀释后）NFBKRGNX
| Q4 25 | $-0.68 | $-1.30 | ||
| Q3 25 | $0.27 | $-1.20 | ||
| Q2 25 | $0.24 | $-1.38 | ||
| Q1 25 | $0.19 | $0.12 | ||
| Q4 24 | $0.27 | $-0.99 | ||
| Q3 24 | $0.16 | $-1.17 | ||
| Q2 24 | $0.14 | $-1.05 | ||
| Q1 24 | $0.15 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $164.0M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $690.1M | $102.7M |
| 总资产 | $5.8B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NFBKRGNX
| Q4 25 | $164.0M | $230.1M | ||
| Q3 25 | $131.7M | $274.2M | ||
| Q2 25 | $97.6M | $323.3M | ||
| Q1 25 | $101.7M | $267.9M | ||
| Q4 24 | $167.7M | $234.7M | ||
| Q3 24 | $232.9M | $255.5M | ||
| Q2 24 | $153.5M | $290.4M | ||
| Q1 24 | $238.8M | $338.7M |
总债务NFBKRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $666.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益NFBKRGNX
| Q4 25 | $690.1M | $102.7M | ||
| Q3 25 | $719.6M | $161.5M | ||
| Q2 25 | $710.3M | $213.7M | ||
| Q1 25 | $711.1M | $274.2M | ||
| Q4 24 | $704.7M | $259.7M | ||
| Q3 24 | $699.6M | $301.4M | ||
| Q2 24 | $693.0M | $348.3M | ||
| Q1 24 | $698.4M | $390.7M |
总资产NFBKRGNX
| Q4 25 | $5.8B | $453.0M | ||
| Q3 25 | $5.7B | $525.2M | ||
| Q2 25 | $5.7B | $581.0M | ||
| Q1 25 | $5.7B | $490.9M | ||
| Q4 24 | $5.7B | $466.0M | ||
| Q3 24 | $5.7B | $519.1M | ||
| Q2 24 | $5.7B | $569.4M | ||
| Q1 24 | $5.9B | $629.2M |
负债/权益比NFBKRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.95× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $53.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $52.5M | $-52.8M |
| 自由现金流率自由现金流/营收 | 127.1% | -174.0% |
| 资本支出强度资本支出/营收 | 2.8% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $89.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NFBKRGNX
| Q4 25 | $53.7M | $-52.3M | ||
| Q3 25 | $13.9M | $-56.0M | ||
| Q2 25 | $14.1M | $-49.3M | ||
| Q1 25 | $9.4M | $33.6M | ||
| Q4 24 | $31.1M | $-31.6M | ||
| Q3 24 | $14.0M | $-40.5M | ||
| Q2 24 | $6.9M | $-45.5M | ||
| Q1 24 | $4.2M | $-55.5M |
自由现金流NFBKRGNX
| Q4 25 | $52.5M | $-52.8M | ||
| Q3 25 | $13.6M | $-56.5M | ||
| Q2 25 | $13.9M | $-49.7M | ||
| Q1 25 | $9.2M | $32.6M | ||
| Q4 24 | $30.0M | $-32.7M | ||
| Q3 24 | $13.7M | $-40.9M | ||
| Q2 24 | $6.7M | $-46.0M | ||
| Q1 24 | $3.8M | $-56.0M |
自由现金流率NFBKRGNX
| Q4 25 | 127.1% | -174.0% | ||
| Q3 25 | 34.6% | -189.9% | ||
| Q2 25 | 35.7% | -232.8% | ||
| Q1 25 | 26.3% | 36.6% | ||
| Q4 24 | 81.6% | -154.2% | ||
| Q3 24 | 43.2% | -168.9% | ||
| Q2 24 | 21.1% | -206.2% | ||
| Q1 24 | 12.1% | -358.5% |
资本支出强度NFBKRGNX
| Q4 25 | 2.8% | 1.7% | ||
| Q3 25 | 0.8% | 1.7% | ||
| Q2 25 | 0.6% | 1.8% | ||
| Q1 25 | 0.7% | 1.2% | ||
| Q4 24 | 3.1% | 5.1% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 0.8% | 2.1% | ||
| Q1 24 | 1.4% | 3.6% |
现金转化率NFBKRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 1.20× | 5.53× | ||
| Q4 24 | 2.76× | — | ||
| Q3 24 | 2.14× | — | ||
| Q2 24 | 1.16× | — | ||
| Q1 24 | 0.68× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NFBK
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
